Sanofi prostate cancer drug shows 28 percent survival

Sanofi prostate cancer drug shows 28 percent survival
Sanofi-Aventis’ cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.

Read more on Reuters via Yahoo! News

More Meth Drug Addiction Info:

• The Real Facts Behind Prostate Cancer | Prostate Cancer Guide
• Quality of Life for Breast and Prostate Cancer Patients Is Better …
• avastin cancer drug | Cancer Blog
• Low-dose Prednisone in Early Rheumatoid Arthritis | RA Education …
• Prednisone Dosage for Rheumatoid Arthritis | RA Education …
• Facts About Prostate Cancer | Geo Blog
• Can Prostate Cancer Can Be Cured? | Geo Blog
• Novartis: Ovarian cancer drug disappoints in trial | CancerType
• Sanofi prostate cancer drug shows 28 percent survival | CADIVIEMPRESAS
• Signaling Protein Spurs Spread of Prostate Cancer, Scientists Find